NF-κB activation is a hallmark of GBM and is driven by oncogenic pathways such as the EGFR and PDGFR signaling pathways, as well as genetic alterations in PTEN, NF1, and ARF. The gene discussed is PDGFRB; the disease is glioblastoma.